To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT ID: NCT00050648

Last Updated: 2009-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-10-31
• Study Completion Date: 2008-04-30

Brief Summary

This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.

Detailed Description

The purpose is to study the safety and effectiveness of a new drug called "anti-TAC" (anti-CD25) Monoclonal Antibody used together with low dose Cyclosporine in the treatment of psoriasis. While the exact cause of psoriasis is unknown, it is believed to involve white blood cells called lymphocytes, which become activated in the skin. It is believed that these activated cells are responsible for the changes you see as the rash of psoriasis. Anti-TAC (anti-CD25) Monoclonal Antibody is designed to block the activation of these lymphocytes. Because the anti-TAC (anti-CD25) Monoclonal Antibody targets the specific cells involved in the symptoms of psoriasis, this new drug may be a better way to treat psoriasis. The second drug, Cyclosporine, is an FDA-approved drug in the treatment of psoriasis. There is evidence in the laboratory that Cyclosporine and anti-TAC, used together, will have an additive effect. An additional benefit of this study is that we are using a lower dose of cyclosporine than is usually given when it is used alone because it is being used together with anti-TAC. This should reduce the side effects usually seen with higher doses of Cyclosporine when it is used as a single drug for psoriasis. The purpose of this study is to test the safety and effectiveness of anti-TAC (Monoclonal Antibody and low dose cyclosporine in patients with active, moderate to severe psoriasis vulgaris. We also hope to gain more information on how anti-TAC works in the body

Conditions

Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

cyclosporine

oral medication 2mg/kg/day orally from Day 0 until Day 90

Group Type: ACTIVE_COMPARATOR

Cyclosporine

Intervention Type: DRUG

2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.

anti-TAC

1mg/kg/dose medication every other week on the odd week (week 1-13)

Group Type: ACTIVE_COMPARATOR

Daclizumab

Intervention Type: DRUG

1mg/kg medication every other week on the odd week (week 1-13).

Cyclosporine and anti-TAC

DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)

Group Type: EXPERIMENTAL

cyclosporine and Daclizumab

Intervention Type: DRUG

1mg/kg plus low dose cyclosporine (2 mg/kg/day)

Interventions

Daclizumab

1mg/kg medication every other week on the odd week (week 1-13).

Intervention Type: DRUG

Cyclosporine

2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.

Intervention Type: DRUG

cyclosporine and Daclizumab

1mg/kg plus low dose cyclosporine (2 mg/kg/day)

Intervention Type: DRUG

Other Intervention Names

Neoral

Eligibility Criteria

Inclusion Criteria

1. Male or female patients with chronic psoriasis vulgaris (disease stable or worsening for > 6 months). Patients age 16 - 21 will be considered on a case by case basis. Patients below 18 will need parental consent.

2. Extensive skin involvement.

3. Scale, thickness, and erythema in individual psoriasis lesions of at least intensity.

4. Psoriasis treated with emollients only for 2 weeks prior to treatment

5. Patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris involving more than 5% of the body surface.

6. History of psoriasis that cannot be treated with topical agents or with previous systemic/ photo(chemo)therapy agents.

Exclusion Criteria

1. . Positive serology for HIV, Hepatitis B, or Hepatitis C.

2. . Positive β-HCG titer. For women of childbearing potential, unwillingness or inability to use a contraceptive device during this study if negative for β-HCG.

3. Guttate psoriasis, pustular psoriasis, or whole body erythroderma.

4. Active infection or persistent fever of unknown origin. 5.) Major concurrent illness, which could worsen following treatment with DaclizumabTM.

6) Any history of an un-treated neoplasm

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Facet Biotech

INDUSTRY

Sponsor Role: collaborator

Rockefeller University

OTHER

Sponsor Role: lead

Responsible Party

Rockefeller University

Principal Investigators

James Krueger, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Rockefeller University

Locations

Rockefeller University Hospital

New York, New York, United States

Rockefeller University

New York, New York, United States

Rockefeller University

New York, New York, United States

Countries

United States

Other Identifiers

JKR-0336

Identifier Type: -

Identifier Source: org_study_id